These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 25531942)

  • 1. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
    Linnemann C; van Buuren MM; Bies L; Verdegaal EM; Schotte R; Calis JJ; Behjati S; Velds A; Hilkmann H; Atmioui DE; Visser M; Stratton MR; Haanen JB; Spits H; van der Burg SH; Schumacher TN
    Nat Med; 2015 Jan; 21(1):81-5. PubMed ID: 25531942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
    Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
    J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
    Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
    J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
    Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
    J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
    Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A
    PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.
    Schmidt J; Smith AR; Magnin M; Racle J; Devlin JR; Bobisse S; Cesbron J; Bonnet V; Carmona SJ; Huber F; Ciriello G; Speiser DE; Bassani-Sternberg M; Coukos G; Baker BM; Harari A; Gfeller D
    Cell Rep Med; 2021 Feb; 2(2):100194. PubMed ID: 33665637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
    Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
    J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
    Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
    Sato N; Nabeta Y; Kondo H; Sahara H; Hirohashi Y; Kashiwagi K; Kanaseki T; Sato Y; Rong S; Hirai I; Kamiguchi K; Tamura Y; Matsuura A; Takahashi S; Torigoe T; Ikeda H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S86-90. PubMed ID: 10950155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells.
    Zhu Z; Cuss SM; Singh V; Gurusamy D; Shoe JL; Leighty R; Bronte V; Hurwitz AA
    J Immunol; 2015 Oct; 195(7):3482-9. PubMed ID: 26320256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma antigens recognised by CD8+ and CD4+ T cells.
    Storkus WJ; Zarour HM
    Forum (Genova); 2000; 10(3):256-70. PubMed ID: 11007933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.
    Van Nuffel AM; Benteyn D; Wilgenhof S; Pierret L; Corthals J; Heirman C; van der Bruggen P; Coulie PG; Neyns B; Thielemans K; Bonehill A
    Mol Ther; 2012 May; 20(5):1063-74. PubMed ID: 22371843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
    Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
    Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.